Inflamax Research today announces a collaboration with the Immune Tolerance Network (ITN), which is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), to conduct clinical research into the underlying mechanisms of allergy.
Mississauga, Ontario (PRWEB) May 21, 2013
Inflamax scientists worked closely with internationally renowned expert scientists of the ITN to design the study, which will provide critical insight into the usefulness of two key clinical models used in the study of allergy treatments, the Environmental Exposure Chamber (EEC) and Nasal Allergen Challenge (NAC) models. Although both the models are well recognized and supported by numerous publications, to date no direct comparison between the allergic responses evoked by them has been performed.
The study involves allergen challenge by the two methods, followed by collection of nasal secretions and blood work to identify the sequence of biomarkers and inflammatory cells involved in the early and late phase of the allergic reaction. Dr. Stephen Durham from the Imperial College London developed the NAC model, and he will be the study’s coordinating investigator. The protocol is being developed by Inflamax and the team at ITN.
“We are pleased that ITN and its group of internationally renowned scientists and clinicians, after reviewing the other available EEC facilities, chose to collaborate with Inflamax on this project. This highlights the unique and very high caliber of scientific expertise and experience that we provide. Collaborations and projects like this underline our core vision and mission to develop and provide the best, scientifically validated models to our clients.” Says Dr Piyush Patel, MD, CEO of Inflamax Research. “Inflamax provides the best of client focused CRO services with scientific expertise which is unparalleled even in the top academic institutions”.
“Sponsor organizations wishing to conduct clinical trials utilizing allergen challenge models including the EEC, need to ensure that the study is properly designed. So doing this kind of basic research reinforces the confidence in data validity, and increases the likelihood that regulators around the world accept the data. The scientific staff at Inflamax have designed and conducted many mechanistic, proof of concept and pivotal studies utilizing multiple allergen challenge models, and are the experts in both scientific design and EEC trial methodology.” says Dr. Anne Marie Salapatek, President and CSO of Inflamax.
Inflamax is developing in-house capability to measure biomarkers and has the expertise to recommend specific biomarkers to assay in order to understand the underlying mechanism of action. Typical markers for consideration may include IL1, IL5, Eosinophil Cationic Protein (ECP), tryptase and Th2 cytokines, specific immunoglobulin (IgG, IgG4, IgA, IgE, and FAB), basophil activation and HLA assays.
Inflamax is a full service Contract Research Organization (CRO) specializing in Proof of Concept as well as Phase I through IV studies in allergy, asthma, ocular and dermatology utilizing EEC technology. Inflamax conducts single and multi-center Environmental Exposure Chamber (EEC) and field studies. In addition to Inflamax Research’s Mobile EECTM systems which can be positioned globally, Inflamax has 2 fixed EECs at Inflamax headquarters in Toronto, Canada. Inflamax’s EECs have been validated for study of allergy to ragweed, grass, cat and dust mite, as well as dry eye syndrome (utilizing low humidity EEC conditions).
The Immune Tolerance Network (ITN) is an international clinical research consortium sponsored by NIAID, part of the National Institutes of Health.
- Cynthia Day O’Brien, Senior Director, Business Development